Abstract
Biofilms are polymeric matrices containing bacteria that can express oncotraits and are frequently present in ulcerative colitis (UC). Oncotraits can impact colon epithelial cells directly and may increase dysplasia risk. This study aimed to determine (1) the association of oncotraits and longitudinal biofilm presence with dysplasia risk in UC, and (2) the relation of bacterial composition with biofilms and dysplasia risk.
In this prospective cohort study, feces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls. Oncotraits (FadA of Fusobacterium, BFT of Bacteroides fragilis, Colibactin (ClbB) and Intimin (Eae) of Escherichia coli) in fecal DNA were assessed with multiplex qPCR. Biopsies were analyzed for biofilms (n=873) with 16S rRNA fluorescent in situ hybridization and shotgun metagenomic sequencing (n=265), and ki67-immunohistochemistry for cell proliferation. Associations were determined with a regression (mixed) model.
ClbB significantly associated with dysplasia in UC (aOR 7.16, (95%CI 1.75-29.28, p<0.01)), while FadA was inversely associated (aOR 0.23, (95%CI 0.06-0.83, p=0.03)). Patients with UC had a significantly lower Shannon diversity compared to controls (p=0.0009), as well as patients with a biofilm (p=0.015) independent of disease status. The order Fusobacteriales was significantly correlated with a decreased dysplasia risk only in right-sided colonic biopsies (p<0.01). Longitudinal biofilms were not significantly associated with dysplasia (aOR 1.45 (95% CI0.63-3.40, p=0.38)), however, biofilm-positive biopsies showed increased epithelial hypertrophy (p=0.025).
Colibactin and FadA impact dysplasia risk in UC, in contrast to biofilms. These oncotraits are valuable targets for future risk classification and intervention studies.
What is already known on this topic Bacterial biofilms sometimes contain bacteria with oncogenic traits (oncotraits) and have been associated with colon carcinogenesis in mice and humans. It is yet unknown whether biofilms and oncotraits are involved in early carcinogenesis and could be used as a risk factor for dysplasia in ulcerative colitis patients.
What this study add Bacterial biofilms associated with lower bacterial diversity and epithelial cell hypertrophy, but did not predict dysplasia. Moreover, in agreement to piling evidence suggesting a role of colibactin in human colorectal cancer, we provide the missing clinical evidence that this oncotrait actually associates with risk for (early) carcinogenesis in human patients. Additionally, dysplasia in UC patients was predicted by absence of Fusobacterium adhesin.
How this study might affect research, practice or policy This prospective cohort study indicates a putative role of bacterial oncotraits in early carcinogenesis, suggesting them as promising targets for future risk classification and intervention studies in ulcerative colitis patients.
Lay summary Patients with ulcerative colitis have an increased risk for colorectal cancer. This study found that bacterial factors in fecal material can predict the development of cancer precursors in these patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Netherlands Organization for Scientific Research (NWO; Veni grant (016.166.089) to AB and Vidi grant (864.14.004) to BED), the Dutch cancer society (KWF-kankerberstrijding grant (KUN 2015-7739)), the European Research Council (ERC; Consolidator grant 865694: DiversiPHI to BED), the Netherlands Organization for Gastroenterology (NVGE; Gastrostart PROJECT 19-2021), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany Excellence Strategy (EXC 2051, Project-ID 390713860) to BED.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee Commissie Mensgebonden onderzoek Arnhem-Nijmegen and the board of directors of the Radboudumc gave ethical approval for this work (NL55930.091.16)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared authorship
Declaration of interest: The authors declare no conflicts of interest
Data Availability: Raw sequencing data with human reads will not be publicly available because of General Data Protection Regulation (GDPR). Processed sequencing data are available upon request. Patient and research data are anonymized and openly available in supplementary data.
Grant support: This work was supported by the Netherlands Organization for Scientific Research (NWO; Veni grant (016.166.089) to AB and Vidi grant (864.14.004) to BED), the Dutch cancer society (KWF-kankerberstrijding grant (KUN 2015-7739)), the European Research Council (ERC; Consolidator grant 865694: DiversiPHI to BED), the Netherlands Organization for Gastroenterology (NVGE; Gastrostart PROJECT 19-2021), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy (EXC 2051 – Project-ID 390713860) to BED.
Data Availability
Raw sequencing data with human reads will not be publicly available because of General Data Protection Regulation (GDPR). Processed sequencing data are available upon request. Anonymized patient and research data that support the findings of this study are openly available in supplementary data.
Abbreviations used in this paper
- IBD
- inflammatory bowel disease
- UC
- ulcerative colitis
- PSC
- primary sclerosing cholangitis
- CRC
- colorectal cancer
- FDR
- First degree relative
- HGD
- high-grade dysplasia
- LGD
- low-grade dysplasia
- SSCAI
- Simple Clinical Colitis Activity Index
- OR
- odds ratio
- aOR
- adjusted odds ratio
- BFT
- Bacteroides fragilis toxin
- qPCR
- quantitative PCR
- n
- number
- IQR
- interquartile range
- IHC
- Immunohistochemistry
- FISH
- Fluorescent in situhybridization
- SD
- standard deviation
- CI
- Confidence interval